Clinical Trial Update: Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the addition of magrolimab to olaparib for BRCA-mutated metastatic breast cancer or castration-resistant prostate cancer has been wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Castration-resistant Prostate Cancer

Drugs mentioned

• Hu5F9-G4 (magrolimab) (magrolimab)
• Lynparza (Olaparib) (Olaparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma | Phase 1 | Status: WITHDRAWN